SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Gilead's headquarters in Silicon Valley
Kidney cancer
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective alternative to Merck’s Welireg in renal cell carcinoma.
February 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of collaborative teamwork featuring human hands in retro collage
Leadership
Leadership Lab: Take a Cue From Athletes by Working With an Executive Coach
Executive coaches can help executives take their game to the next level in four key ways, from improving their self-awareness to reshaping their thinking.
February 19, 2025
 · 
6 min read
 · 
Michael Pietrack
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Pipeline
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.
February 19, 2025
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
RFK Jr.-Linked Lawsuit Against Merck Suspended After Confirmation: Reuters
Recently appointed HHS Secretary Robert F. Kennedy Jr. in 2018 helped bring several cases against vaccine maker Merck, alleging injury linked to its HPV shot Gardasil.
February 19, 2025
 · 
2 min read
 · 
Tristan Manalac
A young business man holding an umbrella to shield himself against a strong headwind. Conceptual image depicting adversity.
Patents
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of the industry’s top-performers are losing key market protections. Some companies are more prepared than others.
February 19, 2025
 · 
10 min read
 · 
Tristan Manalac
Drug Development
Site Survival: Why Clinical Research Sites Need a Lifeline
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
February 19, 2025
 · 
1 min read
 · 
Lori Ellis
Podcast
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom
The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines and psychedelic therapies could be facing very different futures under newly confirmed HHS Secretary Robert F. Kennedy, Jr., Moderna continues its downward revenue slide and Merck, Regeneron, BMS and more face strong patent headwinds.
February 19, 2025
 · 
1 min read
 · 
Heather McKenzie
Poster. Contemporary art collage. Blue and yellow hands peeking out of black holes in space to make a deal. Abstract vibrant artwork. Concept of pop art, positive emotions. Minimal art design.
Rare diseases
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.
February 18, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Risograph Gavel with geometric shapes. Objects in trendy riso graph print texture style design with geometry elements.
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
 · 
1 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS